$248.22 Million Smart Inhalers Markets - Global Forecast to 2025 with COVID-19 Impact Assessment
October 16, 2020 01:33 ET
|
Research and Markets
Dublin, Oct. 16, 2020 (GLOBE NEWSWIRE) -- The "Smart Inhalers Market Research Report by Product Type, by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has...
Asia-Pacific Respiratory Devices Market Report 2020-2025: Market Breakdown by Diagnostic and Monitoring Devices, Therapeutic Devices & Disposables
October 14, 2020 04:14 ET
|
Research and Markets
Dublin, Oct. 14, 2020 (GLOBE NEWSWIRE) -- The "Asia-Pacific Respiratory Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. ...
Global Pneumatic Nebulizers Market Analysis & Forecasts, 2012-2019 & 2020-2027
October 01, 2020 07:24 ET
|
Research and Markets
Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "Pneumatic Nebulizers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Pneumatic...
Global Nebulizers Market Trajectory & Analytics, 2012-2019 & 2020-2027
October 01, 2020 06:44 ET
|
Research and Markets
Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "Nebulizers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Nebulizers Market to Reach...
Nebulizer Market Worth USD 1,778.8 Million at 8.1% CAGR; Large Medical Device Manufacturers Such as Philips and Omron to Develop Products to Deal with the COVID-19 Outbreak: Fortune Business Insights™
September 14, 2020 07:55 ET
|
Fortune Business Insights
Pune, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Global Nebulizer market size is projected to reach USD 1,778.8 million by 2027, exhibiting a CAGR of 8.1% during the forecast period. Increasing prevalence...
InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors
April 03, 2019 08:00 ET
|
InCarda Therapeutics, Inc.
SAN FRANCISCO, April 03, 2019 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies
February 07, 2019 08:05 ET
|
InCarda Therapeutics, Inc.
U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs Additional U.S. Patent Provides Coverage for Combination of...
New 2-in-1 powder aerosol medicine to stop deadly superbugs in the lungs
December 12, 2018 06:00 ET
|
Purdue Research Foundation
West Lafayette, Ind., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Purdue University researchers have developed a new approach to treating the fourth-leading cause of death worldwide – lower respiratory...
InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
November 08, 2018 08:05 ET
|
InCarda Therapeutics, Inc.
Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial...
BioNebicine Corp. Commences Tests of Nebulizer Device
September 04, 2018 13:48 ET
|
BioNebicine Corp.
St. Petersburg, FL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioNebicine Corp. (“BioNebicine” or the “Company”) a privately held biotech company, is pleased to announce that it has...